Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482625 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00482625: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00482625 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00482625, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. This phase II trial is studying how well erlotinib hydrochloride works in treating patients with pancreatic cancer that can be removed by surgery
Primary Outcome
Number of participants showed a reduction in number of positive IPMN cells and staining intensity after treatment
Interventions
- GENETIC protein expression analysis
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- PROCEDURE conventional surgery
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Why NCT00482625 stopped before completion
NCT00482625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00482625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00482625 about?
NCT00482625 is a clinical study titled "Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery". Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. This phase II trial is studying how well erloti...
What is the current status of trial NCT00482625?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2007-06. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00482625?
The interventions under investigation include: protein expression analysis (GENETIC), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), conventional surgery (PROCEDURE), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00482625?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00482625's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia